Stocks Health care ELDN
NASDAQ · Health careEledon Pharmaceuticals, Inc. (ELDN)
It posted a net loss of $98.6M. At June 30, 2026 it held $6.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Eledon Pharmaceuticals, Inc.
- Net worth
- Eledon Pharmaceuticals, Inc. has a market value (market cap) of $233.2M at the latest share price, and shareholders' equity of $33M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $62.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Eledon Pharmaceuticals, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Eledon Pharmaceuticals, Inc. does
Eledon Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ELDN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$45.6M | -$0.52 | n/a |
| 2024 | n/a | -$36.2M | -$0.66 | n/a |
| 2023 | n/a | -$116.5M | -$4.16 | n/a |
| 2022 | n/a | -$88M | -$5.42 | n/a |
| 2021 | n/a | -$34.5M | -$2.05 | n/a |
| 2020 | n/a | -$22.8M | -$13.83 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Eledon Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- September 4, 2026
- August 13, 2026
- August 13, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- June 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 13, 2026
- May 1, 2026
Insider trades
What the people running Eledon Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 31, 2026 | Perrin StevenPresident, Director | Received as pay | 152,353 | - |
| July 31, 2026 | Perrin StevenPresident, Director | Shares withheld for tax | 72,138 | $243.8K |
| July 31, 2026 | Gros David-Alexandre CChief Executive Officer, Director | Received as pay | 354,454 | - |
| July 31, 2026 | Gros David-Alexandre CChief Executive Officer, Director | Shares withheld for tax | 194,791 | $658.4K |
| January 10, 2026 | Robinson James A. Jr.Director | Exercised options | 3,430 | - |
| January 10, 2026 | Lee JuneDirector | Exercised options | 3,430 | - |
| January 10, 2026 | Katkin KeithDirector | Exercised options | 8,575 | - |
| January 10, 2026 | Kirk AllanDirector | Exercised options | 3,430 | - |
Who owns ELDN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | May 15, 2026 |
| Vanguard Capital Management13G, passive | 5.05% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 161 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Bvf Inc | 6,293,282 | 0 |
| BlackRock, Inc. | 5,123,842 | +741,597 |
| Defilade Capital Management, L.P. | 3,525,338 | -38,789 |
| Vanguard Capital Management LLC | 3,417,223 | +124,089 |
| Goldman Sachs Group Inc | 2,510,308 | +2,140,218 |
| Ensign Peak Advisors, Inc | 2,101,224 | -363,695 |
| Geode Capital Management, LLC | 1,956,601 | +164,818 |
| Catalio Capital Management, LP | 1,695,071 | +55,255 |
| State Street Corp | 1,621,969 | +467,298 |
| Zimmer Partners, LP | 1,596,599 | -278,401 |
| Sphera Funds Management Ltd. | 1,191,187 | -580,944 |
| AWM Investment Company, Inc. | 1,100,000 | 0 |
| UBS Group AG | 1,048,245 | +500,798 |
| Kingdon Capital Management, L.L.C. | 1,039,275 | 0 |
| Millennium Management LLC | 979,712 | new |
| Bank of America Corp | 883,097 | +13,553 |
| ADAR1 Capital Management, LLC | 647,812 | -326,609 |
| 22NW, LP | 636,364 | 0 |
| Northern Trust Corp | 616,399 | +72,557 |
| Aqr Capital Management LLC | 581,028 | +408,611 |
Insiders
8 insiders reported holding 275,603 shares in total, about $791K at the last price.
| Holder | Shares |
|---|---|
| Gros David-Alexandre CChief Executive Officer, Director | 168,663 |
| Perrin StevenPresident, Director | 81,215 |
| Katkin KeithDirector | 8,575 |
| Robinson James A. Jr.Director | 3,430 |
| Hillson JanDirector | 3,430 |
| Kirk AllanDirector | 3,430 |
| McBride John S.Director | 3,430 |
| Lee JuneDirector | 3,430 |
Questions about ELDN
What does Eledon Pharmaceuticals, Inc. do?
Eledon Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ELDN. Its shares trade on NASDAQ under the ticker ELDN.
What is Eledon Pharmaceuticals, Inc.'s net worth?
Eledon Pharmaceuticals, Inc. has a market value (market cap) of $233.2M at the latest share price, and shareholders' equity of $33M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Eledon Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $98.6M.
When did Eledon Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 30, 2026.
When is Eledon Pharmaceuticals, Inc.'s next earnings report?
Eledon Pharmaceuticals, Inc.'s next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare ELDN with
Follow ELDN
Get an email when Eledon Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Eledon Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.